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The integrin avb6 is not detectable on normal keratinocytes in vivo but expression is increased signiﬁcantly in oral squamous
cell carcinoma where this heterodimer has been shown to play a role in cell migration, invasion and protease expression.
Although regarded initially as a ﬁbronectin receptor, avb6 may bind to arginine-glycine-aspartic acid sequences in other matrix
molecules including tenascin and vitronectin. Interestingly, avb6 has also been shown to have high afﬁnity for the TGF-b1
latency associated peptide and to participate in the activation of the TGF-b1 latent complex. Since TGF-b1 is present in
squamous carcinomas, it is possible that latency associated peptide may modulate malignant keratinocyte behaviour
independently from the classical TGF-b signalling pathways through its interaction with integrins. We show here that when
latency associated peptide is immobilised onto a surface, it acts as an avb6-speciﬁc ligand for oral squamous carcinoma cells
promoting adhesion and haptotactic migration in addition to avb6-dependent increase in pro-MMP-9 expression. In contrast,
even very low concentrations of soluble latency associated peptide (0.1 mgm l
71) inhibited avb6-dependent adhesion,
migration and invasion. Thus avb6-dependent processes of oral squamous cell carcinoma, is likely to be modulated, not only
by the local concentration of latency associated peptide in the stroma, but also whether it is immobilised in the matrix or
released as a soluble protein.
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TGF-b belongs to a multifunctional cytokine family composed of
three highly homologous genes, TGFB1, TGFB2 and TGFB3 that
encode polypeptides with similar biological functions (Massague
et al, 2000). TGF-b is unusual among the known cytokines as
it is secreted as a latent complex and is found in vivo primarily
in the latent form (Gleizes et al, 1997). The TGF-b isoforms
are synthesised as dimeric precursor proteins, which are cleaved
during secretion to yield mature cytokines. The mature TGF-b
remains associated with its propeptide (the latency-associated
peptide-LAP) as the so-called small latent complex (SLC) from
which TGF-b must be released to elicit its biological activity
(Gleizes et al, 1997). More commonly, the SLC may further
associate with members of another protein family, the latent
TGF-b-binding proteins (LTBPs) forming the large latent complex
(LLC) (Gleizes et al, 1997). The LLC associates with matrix ﬁbrils
and may be incorporated covalently into the extracellular matrix
by cross-linking of LTBP-1 to matrix proteins (Taipale et al,
1996).
LAP-b1 and LAP-b3 isoforms contain an arginine-glycine-
aspartic acid (RGD) sequence, which is also present in a number
of extracellular matrix molecules where it acts as a binding sites
for integrins (Munger et al, 1998). Investigation of latent TGF-
b1 as a possible integrin ligand led to the discovery that A549
lung adenocarcinoma cells adhere to LAP-b1 using avb1 and
avb5 integrins (but migrate on LAP using avb1) (Munger et al,
1998). This study demonstrated that the avidity of avb1 binding
was greater for unbound LAP than when it was complexed as
the SLC or LLC, raising the possibility that integrin binding to
LAP may generate signals independent of classical TGF-b signal-
ling. More recent observations using b6 transfected colon
adenocarcinoma cells revealed that LAP is a high afﬁnity ligand
for avb6 and that the interaction of LAP with avb6 induces phos-
phorylation of downstream components of integrin-signalling
complexes. Furthermore avb6 may provide a mechanism for the
activation of latent TGF-b1 (Munger et al, 1999). Similar to
adenocarcinoma cells, keratinocytes also activate TGF-b1 through
the interaction of avb6 with LAP (Munger et al, 1999). However,
the effect of this protein in modulating keratinocyte behaviour,
particularly cell movement, through integrin interactions has not
been investigated.
The integrin avb6 is expressed primarily on epithelial cells and
binds to RGD sites in ﬁbronectin, vitronectin and tenascin (as well
as LAP) (Busk et al, 1992; Prieto et al, 1993; Huang et al, 1998).
Expression of avb6 is not detectable on keratinocytes in adult oral
epithelium or epidermis. However, several studies have found high
expression of avb6 in oral squamous cell (and other carcinomas),
suggesting that this integrin may play a role in tumour progression
(Breuss et al, 1995; Jones et al, 1997; Arihiro et al, 2000; Hamidi et
al, 2000; Ahmed et al, 2002).
The avb6 heterodimer has been shown to modulate several
processes in keratinocytes, including migration on ﬁbronectin
and vitronectin, and also ﬁbronectin-dependent upregulation of
matrix metalloproteinase-9 (MMP-9) (Huang et al, 1998; Thomas
et al, 2001a). In addition to promoting cell migration and
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www.bjcancer.comMMP-9 upregulation, we have demonstrated that increased expres-
sion of avb6 in squamous cell carcinoma cell lines produces a more
invasive phenotype; such increased aggressive behaviour is avb6-
dependent and is modulated through altered protease expression
(Thomas et al, 2001b,c). A recent study has also shown that the
progression of oral squamous carcinoma in vivo can be signiﬁ-
cantly retarded using inhibitory anti-avb6 antibodies (Xue et al,
2001).
TGF-b is a potent growth inhibitor in normal epithelial tissues
and for this reason considerable emphasis has been given to the
concept that TGF-b is highly protective against cancer, and that
genetic or epigenetic loss of TGF-b signalling leads to tumour
outgrowth and progression (Derynck et al, 2001; Wakeﬁeld and
Roberts, 2002). In addition to growth inhibition, recent work has
implicated TGF-b in other processes involved in tumour inhibition
including maintenance of genomic stability, induction of senes-
cence, suppression of telomerase activity and prevention of
inappropriate angiogenesis (Wakeﬁeld and Roberts, 2002).
However, the role of TGF-b in tumour biology is complex invol-
ving several signalling pathways, and a number of studies have
demonstrated that TGF-b1 may be pro-oncogenic, driving malig-
nant progression, invasion and metastasis (Akhurst and Derynck,
2001; Wakeﬁeld and Roberts, 2002). For example, recent data
suggests that aberrant activation of MAPK pathways may play an
important role in diverting the TGF-b response towards a pro-
oncogenic outcome, and that TGF-b and activated Ras may coop-
erate to promote invasive, metastatic disease (Park et al, 2000). It is
now suggested that TGF-b has biphasic effects during tumorigen-
esis, initially acting as a tumour suppressor, but later stimulating
cancer progression (Akhurst and Balmain, 1999; Akhurst and
Derynck, 2001).
With regard to cancer development in keratinocytes the majority
of studies have focused on the role of TGF-b1 in animal models of
skin carcinogenesis (Akhurst and Balmain, 1999). These have also
demonstrated that TGF-b appears to have biphasic actions on
tumour cells, having an important dominant negative growth effect
at early stages, but at later stages enhancing the malignant conver-
sion rate and invasion through epigenetic mechanisms. A number
of studies have shown that the majority of oral squamous carcinoma
cell lines remain sensitive to the growth inhibitory effect of TGF-b
even in the absence of Smad-4 (suggesting that Smad-4 independent
pathways may also mediate growth inhibitory responses) (Paterson
et al, 1995, 2002; Malliri et al, 1996). However, tumour cells may
escape negative growth regulation by producing less autocrine
TGF-b1, expressing low levels of the receptor TbR-II, or losing
expression of Smad-2 (Fahey et al, 1996; Muro-Cacho et al, 2001;
Paterson et al, 2001). Structural defects in the TbR–I or TbR-II
receptor have also been reported in oral cancers although these
are not common, suggesting that alterations of gene expression
rather than gene mutation are likely to be more important in the
pathogenesis of oral cancer (Garrigue-Antar et al, 1995; Wang et
al, 1997; Paterson et al, 2001). TGF-b1 is frequently detected in
squamous cell carcinomas (Eisma et al, 1996; Akhurst and Balmain,
1999) and it is likely that, independently of tumour cell responses to
classical TGF-b1 signalling, the presence of LAP in the tumour stro-
ma may modulate malignant cell behaviour through its interaction
with integrins.
We have investigated the potential of LAP to modulate oral SCC
behaviour. We report that surface-immobilised LAP, which func-
tions exclusively as an avb6-dependent ligand in keratinocyte-
derived cells, promotes adhesion, migration and increased pro-
MMP-9 secretion. In contrast, soluble LAP mediates avb6-speciﬁc
inhibition of adhesion, migration and invasion. Thus, indepen-
dently of classical TGF-b signalling, the response of oral SCC
cells to TGF-b in vivo is likely to be determined, not only by the
local concentration of LAP but also by the ratio of immobilised
to soluble LAP.
MATERIALS AND METHODS
Antibodies and reagents
A series of monoclonal antibodies (mAbs) (all of murine
origin) was used in this study. Anti-human av (L230; Weinack-
er et al, 1994) was prepared in our laboratory from hybridoma
cells obtained from the American Type Culture Collection
(Rockville, MD, USA). The anti-avb6 (E7P6 and R6G9;
Weinacker et al, 1994), anti-avb6 (10D5; Huang et al, 1998),
anti-a5b1 (P1D6) and anti-b1 (P4C10) antibodies were
purchased from Chemicon International (Harrow, UK). Anti-
avb5 (P1F6) was obtained from Life Technologies, Paisley,
UK. W632 (anti-MHC class I) was a kind gift from W Bodmer
(IMM, Oxford). FITC- and horseradish peroxidase-conjugated
rabbit anti-mouse antibodies were purchased from Dako (High
Wycombe, UK). Plasma ﬁbronectin, TGF-b1 latency associated
peptide (LAP) and BSA were purchased from Sigma Chemical
Co (Poole, Dorset, UK).
Cell cultures
Using cDNA transfection techniques we previously created a
panel of cell lines expressing various levels of avb6 (Thomas et
al, 2001b). H357 is an av-negative oral squamous carcinoma cell
line (Prime et al, 1990; Sugiyama et al, 1993) from which the V3
cell line was generated by transfection of av cDNA (Jones et al,
1996); V3 cells predominantly express the avb5 heterodimer.
This cell line was retrovirally infected with b6 cDNA creating
the VB6 cell line, which has high avb6 expression. A null trans-
fectant control cell line for the VB6 cells (C1) was also generated
at this time (Thomas et al, 2001b). In light of the report of Park
et al (2000) showing the co-activity of activated Ras and TGF-b,
it is perhaps worth noting that H357 cells, and the derivative cell
lines described above, all retain sensitivity to the growth inhibi-
tory effects of TGF-b (Paterson et al, 1995; data not shown)
despite the fact that H357 cells contain c-Ha-ras gene point
mutations at the activating codons 13 and 61 (Yeudall et al,
1993).
Cells were grown in standard keratinocyte growth medium
(KGM) as described (Sugiyama et al, 1993; Jones et al, 1996).
KGM comprised a-MEM containing 10% foetal calf serum (Globe-
pharm, Surrey) supplemented with 100 IU l
71 penicillin,
100 mgl
71 streptomycin and 2.5 mgl
71 amphotericin B (Gibco
BRL), 1.8610
74 M adenine, 5 mgm l
71 insulin, 1610
710 M
cholera toxin, 0.5 mgm l
71 hydrocortisone and 10 ng ml
71 epider-
mal growth factor (Sigma). All cells were tested routinely for
mycoplasma.
Flow cytometry
Subconﬂuent cells were washed twice with PBS and harvested by
trypsin/EDTA (0.25% w v
71,5m M). Cells were washed once in
PBS containing 10% FCS. Cells were incubated with primary anti-
body for 40 min at 48C and washed twice with PBS. FITC-
conjugated secondary antibody was applied to the cells for
30 min at 48C. Brieﬂy, cells were washed twice with PBS and resus-
pended in 0.5 ml PBS with 10% FCS. Labelled cells were scanned
on a FACSCalibur cytometer (Becton-Dickinson) and analysed
using Cellquest software, acquiring 1610
4 events.
Adhesion assays
A5 0ml solution of LAP at a concentration of 0.25 mgm l
71 was
added to 96-well plates (Falcon 3912; Becton Dickinson) and incu-
bated at 378C for 1 h. After incubation wells were washed with PBS
then blocked with 0.1% BSA at 378C for 30 min. Control wells
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51Cr]
labelled (Brunner et al, 1976) and resuspended in PBS containing
2.5 mM EDTA for 10 min. Cells were washed and resuspended in
cold a-MEM (1.5610
4 cells per well). For blocking experiments,
cells were incubated with speciﬁc antibodies (as described in
Results) for 10 min on ice in each well. Plates were incubated at
378C for 30 min. Non-adherent cells were removed by ﬂooding
plates with PBS supplemented with 1 mM CaCl2 and 0.5 mM
MgCl2. After two washes, the plates were cut into individual wells
and the radioactivity associated with each well was determined in a
gamma counter (1261 Multigamma; LKB Wallac, Bromma,
Sweden). The per cent adhesion was expressed as the adherent cell
radioactivity as a proportion of the total cell input. The non-speci-
ﬁc adhesion (attachment to wells coated with BSA) was subtracted.
Experiments were repeated on six occasions in quadruplicate, with
similar results.
Preparation of cell supernatants for MMP determination
Twenty-four-well plates were coated with ﬁbronectin (10 mgm l
71)
or LAP(0.25 mgm l
71). A 200 ml solution was added to the wells
and incubated at 378C for 1 h. After incubation wells were washed
with PBS and blocked with 0.1% BSA for 30 min. 10
5 cells in a-
MEM were seeded into each well. For blocking experiments, cells
were incubated with anti-avb6 antibody (10D5) or an irrelevant
control antibody (W632; anti-MHC CLASS 1) for 30 min at 48C
and plated in medium containing an excess of antibody. Superna-
tant was sampled after 24 h at which time a cell count was carried
out. Conditioned medium was cleared of cells and debris by centri-
fugation at 4000 r.p.m. for 10 min.
Zymography
MMP-9 activity was analysed using SDS–PAGE-substrate gels.
Gelatin (bloom 300, Sigma) was added to a 12% acrylamide
separating gel at a ﬁnal concentration of 1 mg ml
71. To each
gel, supernatant samples containing equal volume/cell number
were mixed with non-reducing sample buffer (62.5 mM Tris-
HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1% bromophenol blue)
and added to the gel without boiling. MMP-9 standard was
run on each gel. Following electrophoresis, gels were washed
twice in 2.5% Triton X-100 for 30 min at 378C to remove the
SDS. Gels were incubated at 378C overnight in developing buffer
containing 50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02%
Triton X-100. Gels were stained with 0.5% Coomassie blue G250
in 30% methanol, 10% glacial acetic acid for 30 min and
destained in the same solution without Coomassie blue. Gela-
tin-degrading enzymes were identiﬁed as clear bands against
the blue background of the stained gel. Images of stained gels
were captured under illumination using the UVP Imagestore
5000 (Ultra-Violet Products UK) and exported for use on a
PC using the Scion image program (Scion Corp; based on the
Macintosh NIH Image program developed at the National Insti-
tutes of Health, USA). The intensity of the bands was measured
by densitometric analysis and comparisons made within each gel
to determine relative changes in MMP activity. Data for each
zymogram were expressed as relative changes in MMP activity
and these relative changes compared with repeat experiments.
Experiments were repeated a minimum of three times in dupli-
cate or triplicate.
Migration assays
Haptotactic cell migration assays were performed using matrix
coated polycarbonate ﬁlters (8 mm pore size, Transwell
1, Beckton
Dickinson). The membrane undersurface was coated with ﬁbronec-
tin (10 mgm l
71) or LAP (0.25 mgm l
71) in PBS for 1 h at 378C
and blocked with migration buffer (0.1% BSA in a-MEM) for
30 min at 378C. For blocking experiments, cells were incubated
with antibody for 30 min at 48C prior to seeding. The lower cham-
ber was ﬁlled with 500 ml of migration buffer, following which cells
were plated in the upper chamber of quadruplicate wells, at a
density of 5610
4 in 100 ml of migration buffer and incubated at
378C for 12 h. Following incubation, the cells in the lower chamber
(including those attached to the undersurface of the membrane)
were trypsinised and counted on a Casy 1 counter (Sharfe System
GmbH, Germany).
Invasion assays
Cell invasion assays were performed using Matrigel coated poly-
carbonate ﬁlters (8 mm pore size, Transwell
1, Beckton
Dickinson). Matrigel (70 ml; 1:2 dilution in a-MEM) was added
to the upper membrane and allowed to gel for 1 h at 378C. For
blocking experiments, cells were incubated with anti-integrin
antibody for 30 min at 48C prior to seeding. To act as a
chemoattractant, 500 ml of KGM was placed in the lower cham-
ber. Cells were plated in the upper chamber of quadruplicate
wells at a density of 5610
4 in 200 mlo fa-MEM and incubated
at 378C for 72 h. The cells in the lower chamber (including
those attached to the undersurface of the membrane) were then
trypsinised and counted on a Casy 1 counter (Sharfe System
GmbH, Germany).
Statistical analysis
Data are expressed as the mean+s.d. of a given number of obser-
vations. Where appropriate, one way analysis of variance
(ANOVA) was used to compare multiple groups. Comparisons
between groups were by Fishers PLSD (set at 5% signiﬁcance). A
P value of 50.05 was considered to be signiﬁcant.
RESULTS
The VB6 cell line expresses high levels of avb6
Figure 1 conﬁrms, as we have shown previously, that VB6 cells
express approximately 50 times more avb6 than C1 cell control
cells. These cell lines do not express avb1o ravb3 (Thomas et
al, 2001b,c). We also conﬁrmed that the gene transfer procedures
had not altered levels of other integrins expressed at the cell surface
by the cells (Thomas et al, 2001b). The cell lines were shown to
express similar levels of b1 integrins (Figure 1). H357 is av-nega-
tive (Figure 1).
Adhesion to LAP is mediated through avb6
Preliminary studies indicated that optimal adhesion to LAP was
achieved at a concentration of 0.25 mgm l
71 (Figure 2A) and that
the level of adhesion at this concentration was similar to that
produced on a ﬁbronectin-coating of 10 mgm l
71 (data not
shown). The cell lines were plated onto LAP in the presence or
absence of blocking antibodies against the av subunit (L230),
b1 subunit (P4C10), avb5 (P1F6), avb6 (10D5), a5b1 (P1D6)
or an irrelevant antibody against MHC class 1 (W632). Over
six separate experiments adhesion of VB6 cells was signiﬁcantly
higher (20% total adhesion) than C1 cells (8.5% total adhesion)
(P=50.001). Adhesion of VB6 cells was inhibited completely by
the anti-avb6 antibody, 10D5 (Figure 2B). Lung adenocarcinoma
cells have been shown previously to bind LAP using avb5
(Munger et al, 1998), however, antibodies against this integrin
had no effect on VB6 adhesion (Figure 2B). Antibodies against
the b1 subunit (P4C10) or a5b1 (P1D6) (Figure 2B) or other a
subunits (including a2, a5, a6 and a9) (data not shown) had
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(8), 859–867no effect on the level of adhesion. Although C1 cells were signiﬁ-
cantly less adhesive under these conditions, inhibition of their
adherence followed a similar pattern and this activity was also
inhibited completely by antibodies against avb6 (Figure 2B). In
order to determine whether other, non-av integrins could bind
to LAP, the adhesion assay was repeated using av negative
H357 cells (Figure 2A). These cells did not adhere to LAP
conﬁrming that adhesion to LAP in the cell lines was modulated
solely through avb6.
Migration towards LAP is avb6-dependent
VB6 cells show increased avb6-dependent migration towards
ﬁbronectin relative to the other cell lines (Thomas et al,
2001b). To determine whether VB6 cells migrated towards
LAP, haptotactic migration assays were performed using LAP-
coated Transwell ﬁlters. VB6 cells migrated less well towards
LAP than ﬁbronectin (a relative reduction of 53% over four
experiments; P=0.039; data not shown). However, migration
towards LAP was increased signiﬁcantly in VB6 cells compared
with C1 cells (P=50.001; (Figure 3A). H357 cells, which are
avb6 negative did not migrate towards LAP and did not differ
signiﬁcantly from random migration towards BSA controls
(Figure 3A).
The migration of VB6 cells towards LAP was abolished by anti-
bodies against the av subunit or avb6 but not by antibodies against
avb5 (Figure 3B). These data combined with the evidence that
H357 cells do not migrate towards LAP, suggest that haptotactic
migration towards LAP by the various cell lines is also modulated
solely through avb6.
Binding of avb6 to LAP induces upregulation of MMP-9
Expression of MMP-9 on BSA-, ﬁbronectin-, and LAP-coated
tissue culture plastic was examined by zymography. Zymography
on supernatant samples from cells grown in serum-free medium
showed that the cells produced predominantly MMP-9 and that
this enzyme was mainly present in proenzyme form. Similar to
the effect observed on ﬁbronectin (Thomas et al, 2001c), VB6 cells
showed signiﬁcant upregulation of MMP-9 when plated on LAP
(P=50.001; Figure 4A,C). This upregulation could be inhibited
by prior incubation of VB6 cells with the speciﬁc anti-avb6 block-
ing antibody, 10D5 (P=50.001; Figure 4B,C). No upregulation of
MMP-9 on LAP was observed in the C1 control cells (P=0.134;
data not shown). These data conﬁrm that, similar to ﬁbronectin,
LAP interaction with the avb6 integrin produces an upregulation
of MMP-9.
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Figure 1 Flow cytometric analysis of integrin expression by cell lines. The
geometric mean ﬂuorescence (arbitrary units, log scale) as measured by
ﬂow cytometry of cells labelled with anti-integrin antibodies is shown. Ne-
gative control had secondary antibody only and has been subtracted from
the results. Figure shows a representative experiment (ND=not detected).
Flow cytometry conﬁrmed high avb6 expression by VB6 cells and that C1
null transfectant cells express low levels of endogenous avb6. H357 cells
are av- negative. The cell lines express similar levels of b1 integrins.
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Figure 2 Cell adhesion to LAP is avb6-dependent. Chromium [
51Cr]-
labelled cells (1.5610
4) were added to LAP-coated 96-well plates contain-
ing an irrelevant control antibody (W632 anti-MHC class 1) or test antibo-
dies against av (L230), avb5 (P1F6), avb6 (10D5), b1 (P4C10) and a5b1
(P1D6). Background binding to BSA has been subtracted from the results.
Figures show representative experiments performed in quadruplicate. Error
bars represent standard deviation. (A) VB6 cells show increased adherence
LAP. b6 transfected cells (VB6), control cells (C1) and av-negative cells
(H357) were plated onto varying concentrations of LAP. VB6 cells showed
signiﬁcantly increased adhesion compared to C1 cells (which express low
levels of endogenous avb6). H357 cells did not adhere. (B) Adhesion to
LAP is avb6-dependent. VB6 and C1 adhesion to LAP was inhibited by
anti-avb6 antibody or anti-av antibody. Antibodies against avb5, a5b1o r
b1 produced no effect. These data suggest that adhesion of VB6 and C1
cells is modulated solely through avb6.
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British Journal of Cancer (2002) 87(8), 859–867 ã 2002 Cancer Research UKSoluble LAP inhibits adhesion and migration of VB6 cells
to ﬁbronectin
VB6 cells bind to ﬁbronectin through both avb6 and a5b1 integ-
rins such that to completely inhibit adhesion to this substrate, a
combination of blocking antibodies against both integrins is
required (Thomas et al, 2001b). To determine whether LAP
competitively inhibits avb6-dependent binding to ﬁbronectin,
VB6 cells were incubated with LAP (0.25 mgm l
71) or antibodies
against avb6 (10D5) or a5b1 (P1D6) prior to plating. Treating
the cells solely with LAP, or antibodies against avb6o ra5b1 did
not inhibit adhesion to ﬁbronectin signiﬁcantly (Figure 5A). Simi-
larly, a combination of LAP and anti-avb6 produced no signiﬁcant
effect. However, a combination of anti-a5b1 and LAP (or a combi-
nation of anti-a5b1 and anti-avb6) completely inhibited adhesion
to ﬁbronectin (Figure 5A). These data are consistent with the
possibility that soluble LAP may alter keratinocyte binding to
ﬁbronectin through its interaction with the avb6 integrin.
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Figure 3 Cell migration towards LAP is avb6-dependent. Cells were al-
lowed to migrate towards LAP in haptotactic migration assays. To assess
integrin speciﬁcity of migration, integrin-blocking antibodies against av
(L230), avb5 (P1F6), avb6 (10D5), or a control antibody (W632) were
added to VB6, C1 and H357 cells prior to plating into wells. Following
8 h incubation, the cells in the lower chamber (including those attached
to the undersurface of the membrane) were trypsinised and counted on
a Casy 1 counter (Sharfe System GmbH, Germany). Results for the cell
lines are expressed relative to VB6 migration following incubation with
an irrelevant control antibody (=100). Figures show representative experi-
ments performed in quadruplicate. Error bars represent standard deviation.
(A) VB6 cells show increased migration towards LAP. Comparison of mi-
gration of VB6, C1 and H357 cells towards LAP. Migration is higher in the
avb6 expressing VB6 cells. av-negative H357 cells did not migrate signiﬁ-
cantly. (B) Migration towards LAP is avb6-dependent. Migration of VB6
and C1 cells was inhibited completely by antibody inhibition of avb6o r
av. Antibodies inhibiting avb5 produced no effect. These data suggest that
migration of VB6 and C1 cells is modulated solely through avb6.
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Figure 4 Binding of avb6 to LAP induces upregulation of MMP-9. Zymo-
graphy for MMP-9. Cells were grown for 24 h in additive-free medium be-
fore supernatant sampling and cell counting. Samples containing equal
volume per cell number were run on each gel with MMP-9 control. The
intensity of the bands was measured by densitometric analysis and compar-
isons made within each gel to determine relative changes in MMP activity.
(A) Zymogram showing upregulation of MMP-9 expression by VB6 cells
when plated on ﬁbronectin (FN) and LAP relative to BSA-coated plastic.
Control is pro-MMP-9. (B) Zymogram showing the inhibition of MMP-9
expression by VB6 cells plated onto LAP following blockade with anti-
avb6 antibody 10D5 relative to an irrelevant control antibody (Ctl;
W632 (anti-MHC class 1)). (C) Densitometric analysis of zymograms from
multiple separate experiments (n=4) showing MMP-9 expression by VB6
cells on BSA, LAP following incubation with an irrelevant control antibody
(Ctl; W632 (anti-MHC class 1)) and LAP following blockade with anti-avb6
antibody (10D5). Results are expressed relative to MMP-9 expression by
VB6 cells on BSA-coated plastic (=100). Error bars represent standard de-
viation. These data suggest that avb6-LAP interaction modulates MMP-9
expression in VB6 cells.
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Figure 5 Soluble LAP inhibits avb6 interaction with ﬁbronectin. (A) LAP inhibits VB6 adhesion to ﬁbronectin. Chromium [
51Cr]-labelled VB6 cells were
added to ﬁbronectin-coated 96-well plates containing an irrelevant control antibody (W632) or test antibodies against avb6 (10D5), a5b1 (P1D6) and LAP
(0.25 mgm l
71) or combinations thereof. Figure shows a representative experiment performed in quadruplicate. Results are expressed relative to binding in
the presence of a control antibody (=100). Background binding to BSA has been subtracted from the results. Error bars represent standard deviation. VB6
cells adhere to ﬁbronectin through avb6 and a5b1 and a combination of antibodies against both integrins is required to block adhesion completely (Thomas
et al, 2001b). Treating the cells solely with LAP, or antibodies against avb6o ra5b1 did not inhibit adhesion signiﬁcantly (neither did a combination of LAP
and anti-avb6). However, combinations of anti-a5b1 and LAP or anti-avb6 and anti-a5b1 inhibited adhesion completely. These data conﬁrm that soluble
LAP produces a similar effect to anti-avb6 antibody and suggests that LAP may alter keratinocyte binding to ﬁbronectin through its interaction with the avb6
integrin. (B) LAP inhibits VB6 migration to ﬁbronectin. To determine the effect of LAP on cell migration, the cells were treated with varying concentrations
of LAP peptide prior to plating and then allowed to migrate for 8 h before counting. A representative experiment performed in quadruplicate is shown.
Results are expressed relative to migration in the presence of a control antibody (=100). Error bars represent standard deviation. Haptotactic migration of
VB6 cells towards ﬁbronectin is modulated through avb6 and a5b1 integrins and maximal inhibition of migration is produced by blocking both integrins
(Thomas et al, 2001b). Migration of VB6 cells towards ﬁbronectin was inhibited by a concentration of LAP as low as 0.1 mgm l
71 (51% inhibition). At higher
concentrations a further degree of inhibition was seen (0.25 mgm l
71=63% inhibition). This level of inhibition was similar to that produced by anti-avb6
antibody (54% inhibition) and did not differ signiﬁcantly from a combination of LAP and anti-avb6 antibody (52% inhibition). Complete inhibition of migra-
tion was produced using a combination of soluble LAP with anti-a5b1 antibody (or a combination of anti-avb6 with anti-a5b1 antibody). Soluble LAP had
no effect of the migration of H357 av-negative cells. These data conﬁrm that soluble LAP produces a similar effect to anti-avb6 antibody and suggest that
LAP may inhibit avb6-dependent keratinocyte migration towards ﬁbronectin. (C) LAP inhibits avb6-dependent invasion through Matrigel. Cell invasion
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modulated through avb6 and a5b1 integrins (Thomas et al,
2001b). To determine whether LAP inhibits avb6-dependent
migration towards ﬁbronectin, VB6 cells were incubated with vary-
ing concentrations of LAP prior to plating. A titration of LAP
concentrations showed that migration towards ﬁbronectin could
be inhibited by a concentration of LAP as low as 0.1 mgm l
71
(51% inhibition; P=0.001; Figure 5B). At higher concentrations a
further degree of inhibition was seen (0.25 mgm l
71=63% inhibi-
tion; P=0.001; Figure 5B). This inhibition was similar to that
produced by anti-avb6 antibody alone or a combination of LAP
and anti-avb6 antibody (46 and 48% inhibition respectively; Figure
5B). Complete inhibition of migration was produced using a
combination of LAP with anti-a5b1 antibody or (as demonstrated
previously), a combination of anti-a5b1 and anti-avb6 antibodies
(Thomas et al, 2001b). Migration of av-negative H357 cells
towards ﬁbronectin was not affected by the presence of LAP in
the assay. These data suggest that LAP may inhibit avb6-dependent
keratinocyte migration towards ﬁbronectin.
Soluble LAP inhibits invasion of VB6 cells through
Matrigel
VB6 cells show increased avb6-dependent invasion through Matri-
gel relative to C1 control cells (Thomas et al, 2001b,c). To
determine whether LAP inhibits avb6-dependent invasion, VB6
cells were incubated with LAP (0.5 mgm l
71) or antibodies against
the av subunit, avb6o ra5b1. Figure 5C conﬁrms that prior incu-
bation of VB6 cells with LAP inhibits invasion by VB6 cells (62%
inhibition; P=50.001), producing a similar level of inhibition to
that obtained with anti-avb6 antibody (58% inhibition). Invasion
of H357 cells (which invade at a similar level to VB6 cells through
non-avb6 mechanism) or C1 cells was not affected by LAP. In
addition, to conﬁrm that cell invasion was not affected by endo-
genously secreted TGF-b1 or by TGF-b1 present within serum,
we repeated the assays incorporating a TGF-b1 blocking antibody
or TGF-b1 soluble receptor. Neither of these TGF-b inhibitors
produced an effect on invasion by VB6 cells (data not shown).
These data conﬁrm that soluble LAP may speciﬁcally inhibit
avb6-dependent cell invasion.
DISCUSSION
De novo expression of avb6 is seen in a number of epithelial malig-
nancies, particularly oral squamous cell carcinoma (SCC) (Breuss
et al, 1995; Jones et al, 1997; Hamidi et al, 2000; Ahmed et al,
2002). Expression of this integrin is often higher at the invasive
front, supporting the contention that avb6 is capable of playing
an active role in tumour progression. We have shown previously
that over-expression of avb6 in oral SCC cells promotes cell migra-
tion, invasion and MMP-9 expression (Thomas et al, 2001b, c).
Moreover, recent data from Xue et al (2001) demonstrated that
inhibition of avb6 could signiﬁcantly retard the growth of human
SCC cells implanted orthotopically into athymic mice. These
studies provide strong evidence that the activity of avb6 promotes
development of SCC and that this integrin may represent a possible
therapeutic target in the treatment of SCC. It is therefore essential
that we gain a complete understanding of how interaction of avb6
with its immediate environment can result in changes in cell beha-
viour.
The principal extracellular matrix ligands for avb6 are ﬁbronec-
tin and tenascin, although avb6 also modulates migration on
vitronectin (Busk et al, 1992; Prieto et al, 1993; Huang et al,
1998). All three ligands are found in relative abundance at sites
of tumour growth (Mighell et al, 1997; Johnsen et al, 1998; Ramos
et al, 1998; Kosmehl et al, 1999). Recently it has been shown that
avb6 binds to and activates latent TGF-b1 and TGF-b3 via an
interaction with its pro-peptide, the latency-associated peptide
(LAP) (Munger et al, 1999; Annes et al, 2002). Since changes in
the local concentration of TGF-b1/LAP occur naturally during
SCC, we investigated whether LAP could modulate avb6-depen-
dent activities and thus the biological behaviour of transformed
keratinocytes.
The role of TGF-b1 in SCC is complex. Studies suggest that
TGF-b1 has biphasic actions on tumour cells, having an impor-
tant negative growth effect in the early stages of carcinogenesis,
but at later stages enhancing invasion and metastasis through
epigenetic mechanisms (Akhurst and Balmain, 1999; Akhurst
and Derynck, 2001). Recent data suggests that aberrant activation
of MAPK pathways may play an important role in diverting the
TGF-b response towards a pro-oncogenic outcome, and that
TGF-b and activated Ras may cooperate to promote invasive,
metastatic disease (Park et al, 2000). However, Ras mutations
are uncommon in SCC in the western world (Rumsby et al,
1990; Yeudall et al, 1993). Moreover, although the parental cell
line H357, used in this study, harbours two point mutations in
the c-Ha-ras gene (Yeudall et al, 1993) it retains its sensitivity
to the growth inhibitory effects of TGF-b1 (Paterson et al,
1995). In fact, the majority of studies have found that oral SCC
cell lines are growth inhibited by TGF-b1 (Paterson et al, 1995;
Malliri et al, 1996). A recent study has shown that TGF-b-depen-
dent growth inhibition of oral SCC cells may occur in the absence
of Smad-4, a key molecule in TGF-b signalling (Akhurst and
Derynck, 2001; Derynck et al, 2001), suggesting that other signal-
ling pathways may also mediate growth inhibitory responses
(Paterson et al, 2002). Several mechanisms by which oral SCC
may escape the negative growth regulation of TGF-b include
producing less autocrine TGF-b1, expressing low levels of the
receptor TbR-II or losing expression of Smad-2 (Fahey et al,
1996; Muro-Cacho et al, 2001; Paterson et al, 2001). Although
structural defects in the TbR-I and TbR-II receptors have been
reported in oral SCC, these are not common. These data suggest
that alterations of gene expression are likely to be more important
than mutations in the pathogenesis of oral SCC (Garrigue-Antar
et al, 1995; Wang et al, 1997; Paterson et al, 2001). TGF-b is
frequently detectable in SCC, particularly in the more advanced
stages of tumour progression, and relatively high concentrations
of TGF-b are usually found in tumour stroma (reviewed by
Pasche, 2001). Thus there is a signiﬁcant likelihood that TGF-b
could affect SCC tumour cell behaviour via integrin-dependent
interaction with its pro-peptide, LAP, independent of classical
TGF-b signalling.
We ﬁrst determined how keratinocyte-derived cells adhered to
LAP. It has been reported that in addition to avb6, avb5 and
avb1 can also serve as receptors for LAP (Munger et al, 1998).
We report here that although the oral SCC cells used in this study
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assays were performed over 72 h using Matrigel coated polycarbonate ﬁlters. To assess the effect of soluble LAP invasion, cells were treated with LAP
(0.5 mgm l
71) for 30 min at 48C prior to plating. Following incubation the cells in the lower chamber (including those attached to the undersurface of
the membrane) were trypsinised and counted on a Casy 1 counter (Sharfe System GmbH, Germany). Figure shows a representative experiment performed
in quadruplicate. Error bars represent standard deviation. Pre-incubation of VB6 cells with soluble LAP inhibited invasion (62% inhibition), producing a similar
level of inhibition to anti-avb6 antibody (58% inhibition). Soluble LAP had no effect on invasion of H357 av-negative cells or C1 control cells which express
low levels of endogenous avb6. These data suggest that soluble LAP may inhibit avb6-dependent cell invasion.
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derived cells bind and migrate towards LAP solely via avb6. These
ﬁndings were conﬁrmed using primary keratinocytes (which
express avb6 and avb5 in vitro), which also bind to and migrate
toward LAP solely through avb6 (data not shown). The oral
SCC line, VB6, exhibited haptotactic migration toward LAP,
although at signiﬁcantly lower levels than VB6 migration towards
ﬁbronectin. Interestingly, avb6-dependent cell invasion of VB6 cells
was observed when serum was replaced with LAP (or ﬁbronectin)
in the lower chamber of the invasion assay. It would seem that
these matrix proteins act as chemoattractants for avb6-dependent
invasion. LAP also induced an avb6-dependent upregulation of
pro-MMP-9 expression, as was previously shown on ﬁbronectin
(Thomas et al, 2001a,c). It appears therefore that LAP modulates
similar avb6-dependent functions as ﬁbronectin.
The interaction between avb6 and TGF-b in SCC appears
complex. It is possible that avb6 may activate TGF-b1 and produce
a growth inhibitory effect, whereas, depending on whether LAP is
immobilised in the ECM or present as a soluble ligand, it is also
possible that LAP could modulate both cell movement and
protease production. The net effect on tumour behaviour may
depend on the stage of tumour development. Growth inhibition
may be dominant in the earlier stages of carcinogenesis with
TGF-b1 acting as a tumour suppressor. However, in the later stages
of tumour development, as cells become refractory to growth inhi-
bition, then the role of LAP in promoting avb6-dependent cell
movement and MMP-9 expression may assume greater signiﬁ-
cance, and this may be one of the ways in which TGF-b
promotes tumour development.
In summary, previously we reported that it was likely that avb6
promoted oral SCC invasion by increasing migration, pro-MMP9
production and invasion (Thomas et al, 2001b,c). In this study
we now show that these avb6-dependent processes of oral SCC
cells are likely to be modulated in vivo by ligation to a high-afﬁ-
nity, avb6-speciﬁc ligand for oral SCC cells, the TGFb-associated
pro-peptide, LAP.
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